Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 23;77(9):2852-2856.
doi: 10.1111/all.15385. Online ahead of print.

Metabolomics to identify omalizumab responders among children with severe asthma: a prospective study

Silvia Carraro  1 , Emanuela di Palmo  2 , Amelia Licari  3 , Simona Barni  4 , Valeria Caldarelli  5 , Giovanna De Castro  6 , Antonio Di Marco  7 , Grazia Fenu  8 , Giuseppe Giordano  9   10 , Enrico Lombardi  8 , Paola Pirillo  9   10 , Matteo Stocchero  9   10 , Alessandro Volpini  11 , Stefania Zanconato  1 , Franca Rusconi  12 ; Italian Paediatric Severe Asthma Network (IPSAN)
Affiliations

Metabolomics to identify omalizumab responders among children with severe asthma: a prospective study

Silvia Carraro et al. Allergy. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

GF reports financial and non‐financial support from AstraZeneca, Chiesi, Boehringer Ingelheim, GSK, Novartis, Sanofi, outside this work: AV reports financial or non‐financial support from Chiesi, Fidia Sooft, Momento Medico, Lusofarmaco, outside this work; EL reports financial and non‐financial support from AbbVie, Angelini, Boehringer, Chiesi, GlaxoSmithKline, Lusofarmaco, Novartis, Restech, Sanofi, Vertex, outside this work; SZ reports financial support from Sanofi, outside this work; AdM reports financial support from GlaxoSmithKline and Sanofi, outside this work. SC, EdP, FR, SB, PP, GDC, VC, AL, GG, MS, report no conflict of interest for this manuscript.

Figures

FIGURE 1
FIGURE 1
Boxplots showing the distributions of the features selected by Mood's test controlling the false discovery rate by Storey method (adjusted‐p < .15); green bars: non‐responders (NR); yellow bars: responders (R); variables are indicated as [ionization mode][ID][group]
See this image and copyright information in PMC

References

    1. Chipps BE, Lanier B, Milgrom H, et al. Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real‐world experience. J Allergy Clin Immunol. 2017;139:1431‐1444. - PubMed
    1. Deschildre A, Marguet C, Salleron J, et al. Add‐on omalizumab in children with severe allergic asthma: a 1‐year real life survey. Eur Respir J. 2013;42:1224‐1233. - PubMed
    1. Carraro S, Giordano G, Reniero F, Perilongo G, Baraldi E. Metabolomics: a new frontier for research in pediatrics. J Pediatr. 2009;154:638‐644. - PubMed
    1. Bousquet J, Humbert M, Gibson PG, et al. Real‐world effectiveness of omalizumab in severe allergic asthma: a meta‐analysis of observational studies. J Allergy Clin Immunol Pract. 2021;9:2702‐2714. - PubMed
    1. Wildfire JJ, Gergen PJ, Sorkness CA, et al. Development and validation of the Composite Asthma Severity Index—an outcome measure for use in children and adolescents. J Allergy Clin Immunol. 2012;129:694‐701. - PMC - PubMed

LinkOut - more resources